StockData

Aquestive Therapeutics vs Fortress Biotech

AQST and FBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AQST and FBIO compare

Aquestive Therapeutics is the larger company, worth 6.9 times as much as Fortress Biotech ($464M against $66.9M).

Aquestive Therapeutics grew revenue faster over the last twelve months (22.6% versus 15.5% for Fortress Biotech).

Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 163% compared with −145% at Aquestive Therapeutics.

Fortress Biotech scores higher on the StockData Score (9 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAQSTFBIO
Size and price
Market cap$464M$66.9M
Share price$3.70$1.82
Change, 1 year−31.4%−30.5%
Change, 5 years−41.9%−95.7%
Beta (5Y)1.200.64
Employees14778
StockData Score
Total score39 (better)
Valuation score01 (better)
Growth score2 (better)1
Performance score03 (better)
Health score14 (better)
Dividend score00
Valuation
P/S8.6×1.0× (better)
P/B–0.4×
FCF yield−9.9%–
Growth
Revenue growth (TTM)22.6% (better)15.5%
Revenue growth, 5Y average−0.58%6.8% (better)
Profitability
Gross margin67.0% (better)65.6%
Operating margin−97.5%−42.9% (better)
Net margin−145%163% (better)
FCF margin−85.0%–
Return on equity–107%
Return on invested capital–−261%
Financial health
Debt / equity–0.21
Interest coverage−4.7×−3.0× (better)
Current ratio7.19 (better)3.96
Altman Z-score−3.57−1.79 (better)
Piotroski F-score26 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions57.4%15.9%
Held by insiders3.2%31.6%
Insider net buying, 12 months−$2.3M–
Short interest, % of float24.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.